National Cancer Center Hospital East

Kashiwa-shi 277-8577

8 studies enrolling now · 20 studies all time

What they study most

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Advanced Cholangiocarcinoma, Advanced Solid Tumor, Advanced Solid Tumors, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, CRC (Colorectal Cancer), Cancer, Carcinoma, Non-Small-Cell Lung, Cervical Cancer, Cholangiocarcinoma

Studies at this site

• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors — Recruiting now
• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer — Recruiting now
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread — Recruiting now
• SMP-3124LP in Adults With Advanced Solid Tumors — Recruiting now
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — Recruiting now
• Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement — Recruiting now
• Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer — Recruiting now
• A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) — Recruiting now
• Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) — Running, not enrolling
• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) — Running, not enrolling
• Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) — Running, not enrolling
• A Study of ZW191 in Participants With Solid Tumors — Running, not enrolling
• Bintrafusp Alfa Program Rollover Study — Completed
• A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Running, not enrolling
• Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) — Completed
• Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC — Stopped early
• M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) — Completed
• Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) — Completed